Amgen upgraded at Wells Fargo citing a post-Horizon deal opportunity
JHVEPhoto/iStock Editorial via Getty Images
Amgen (NASDAQ:AMGN) traded higher Monday morning after Wells Fargo upgraded it to Overweight from Equal Weight citing an opportunity following the company's ~$28B deal to acquire rare disease drugmaker Horizon Therapeutics (HZNP).
- "While we are not big fans of the HZNP deal and the price at which it was done, we note that it is in the rear-view mirror now," the analyst Mohit Bansal and the team wrote, adding that concerns on the acquisition have caused weakness.
- Assuming no U.S. sales growth for Horizon's (HZNP) thyroid eye disease therapy Tepezza, and modest growth for the company's other divisions, the analysts see $247 future value for Amgen (AMGN).
- The team noted that "the stock is trading below this level," adding, "AMGN's marketing strength makes worst case less likely."
- However, Wells Fargo lowered the Amgen (AMGN) price target to $265 from $275 based on DCF valuation.
- Read: Seeking Alpha contributor Edmund Ingham upgraded Amgen (AMGN) to Buy from Hold after the company's FY22 results.